Sartorius Stedim Biotech (FR:DIM)
:DIM
Want to see FR:DIM full AI Analyst Report?
DIM Stock Chart & Stats
€188.70
€3.85(1.94%)
At close: 4:00 PM EST
€188.70
€3.85(1.94%)
Day’s Range― - ―
52-Week Range€150.00 - €224.00
Previous CloseN/A
Volume6.35K
Average Volume (3M)78.09K
Market Cap
€17.30B
Enterprise Value€19.42B
Total Cash (Recent Filing)€521.20M
Total Debt (Recent Filing)€2.61B
Price to Earnings (P/E)64.5
Beta1.42
Next Earnings
Jul 23, 2026EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)2.75
Shares Outstanding97,330,410
10 Day Avg. Volume78,938
30 Day Avg. Volume78,094
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€232.63Price Target Upside23.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.1
Revenue Forecast (FY)€3.17B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA strong 57% TTM revenue rebound restores scale and improves utilization of capital equipment and consumable production lines. Sustained top-line recovery supports recurring sales, helps absorb fixed costs, funds reinvestment in capacity and R&D, and underpins medium-term margin recovery.
Recurring Consumables ModelHigh-repeat consumable sales create durable, predictable revenue streams tied to customers' manufacturing throughput. This installed-base-driven model increases customer stickiness, supports recurring margins, smooths revenue across cycles, and provides a stable base for cross-selling instruments and services.
Solid Operating MarginsEBIT and EBITDA margins near mid-teens/upper-20s indicate structurally efficient operations and pricing power in bioprocessing. These margins provide cash to fund capex, service the installed base and invest in product development, supporting sustainable competitiveness despite prior peak compression.
Bears Say
Margin CompressionSubstantial decline from prior peak margins suggests structural pressures: mix shifts, pricing dynamics or higher costs. Persistent margin compression limits net earnings power, reduces return on invested capital and makes funding growth or shareholder returns harder without enduring productivity gains or price recovery.
Weak FCF ConversionRelatively low conversion of operating cash to free cash flow constrains ability to deleverage, expand capacity or increase distributions. Persistent working-capital absorption or elevated reinvestment needs can keep FCF depressed, raising financing sensitivity and slowing structural improvement in returns.
Sizeable Debt And Low ROEAlthough leverage has improved, absolute debt remains material and ROE is modest, indicating limited capital efficiency. Ongoing debt service reduces strategic flexibility for acquisitions or aggressive capex, and subdued ROE implies the business currently generates only low incremental returns on shareholder capital.
Sartorius Stedim Biotech News
DIM FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €150.00 and its highest was €224.00 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €17.30B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Jul 23, 2026 which is in 42 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Apr 23, 2026. The company reported €1.17 earnings per share for the quarter, missing the consensus estimate of €1.211 by -€0.041.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Notavailable dividend of €0.69 which represents an annual dividend yield of 0.31%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.3.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.17 in its last earnings report, missing expectations of €1.211. Following the earnings report the stock price went down -14.185%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in FR:DIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
DIM Stock 12 Month Forecast
Average Price Target
€232.63
▲(23.28% Upside)
Technical Analysis
Options Prices
Currently, No data available
---